Google
Trusted Resources: News & Events
Latest announcements and gatherings
Researchers raise funds for phase 1 trial to test medical cannabis in sickle cell disease
The Sickle Cell Foundation of Georgia (SCFG) has partnered with Biotech Research Laboratories and the Phoenix Tears Foundation to raise money for the first clinical study focused on the effectiveness of cannabis oil in sickle cell disease (SCD)-related pain management.
The initiative is in honor of World Sickle Cell Day, held annually on June 19 to mark the day the United Nations General Assembly recognized SCD as a public health problem.
“We urge the Sickle Cell community, our friends and allies to join in supporting the coalition as we search for alternative treatments for those battling this painful and sometimes fatal condition,” Deb McGhee McCrary, SCFG president and CEO, said in a news release. “These trials will fully explore the pain relief properties of medical cannabis as an alternative to highly addictive opioids.”
+myBinderRelated Content
-
Yoga for Chronic Pain – US Pain FoundationDuring this interactive live webinar, in...
-
A randomized controlled pilot study feasibility of a tablet-based guided audio-visual relaxation intervention for re...AIM: To test feasibility of a guided aud...
-
The effects of music therapy on transition outcomes in adolescents and young adults with sickle cell diseaseBackground: The Build, Educate, Advance...
-
Imara Reports Favorable Preclinical and Phase 1 Data on IMR-687 in Sickle Cell DiseaseImara Inc. today announced it will repor...
-
Imara’s IMR-687 for SCD Receives FDA Rare Pediatric Disease DesignationThe U.S. Food and Drug Administration (F...
-
California’s Stem Cell Agency Invests in Stem Cell-Based Therapies Targeting Sickle Cell Disease and CancerThe California Institute for Regenerativ...
-
Let Your Light Shine: Yoga & MeditationPiedmont Health Services and Sickle Cell...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.